Cargando…

Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study

BACKGROUND: Efficacy of treatments for colorectal liver metastases after failure of first-line chemotherapy is limited. The aim of this study was to prospectively evaluate the feasibility, tolerability, and pharmacokinetics of selective transarterial chemoembolization (TACE) with irinotecan-loaded 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Toshihiro, Sato, Takeshi, Nishiofuku, Hideyuki, Masada, Tetsuya, Tatsumoto, Shota, Marugami, Nagaaki, Otsuji, Toshio, Kanno, Masatoshi, Koyama, Fumikazu, Sho, Masayuki, Kichikawa, Kimihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670239/ https://www.ncbi.nlm.nih.gov/pubmed/31370815 http://dx.doi.org/10.1186/s12885-019-5862-3

Ejemplares similares

Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
por: Nishiofuku, Hideyuki, et al.
Publicado: (2015)

Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model
por: Taiji, Ryosuke, et al.
Publicado: (2021)

The middle rectal artery detected by contrast-enhanced magnetic resonance imaging predicts lateral lymph node metastasis in lower rectal cancer
por: Iwasa, Yosuke, et al.
Publicado: (2021)

Development of liposomal contrast agent with high iodine concentration and minimal effect on renal function
por: Ochi, Tomoko, et al.
Publicado: (2023)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Cellular Imaging Using Equivalent Cross-Relaxation Rate Technique in Rabbit VX-2 Tumor Model
por: Nishiofuku, Hideyuki, et al.
Publicado: (2011)

FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping
por: Lu, Chien-Yu, et al.
Publicado: (2014)

Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria
por: Saito, Natsuhiko, et al.
Publicado: (2023)

Imaging features of β-catenin-activated hepatocellular adenoma with weak β-catenin activation: A rare case report
por: Minamiguchi, Kiyoyuki, et al.
Publicado: (2022)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

Quantitative Analysis of Signal Heterogeneity in the Hepatobiliary Phase of Pretreatment Gadoxetic Acid-Enhanced MRI as a Prognostic Imaging Biomarker in Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma
por: Minamiguchi, Kiyoyuki, et al.
Publicado: (2023)

Cellular Density Evaluation for Malignant Lymphoma Using Equivalent Cross-Relaxation Rate Imaging - Initial Experience
por: Nishiofuku, Hideyuki, et al.
Publicado: (2010)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Tachiiri, Tetsuya, et al.
Publicado: (2023)

Ultrasonic Heating Detects Lipiodol Deposition within Liver Tumors after Transarterial Embolization: An In Vivo Approach
por: Saito, Natsuhiko, et al.
Publicado: (2021)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
por: Ma, Cheng-Jen, et al.
Publicado: (2019)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
por: Páez, David, et al.
Publicado: (2018)

Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer
por: Lee, Myung-Ah, et al.
Publicado: (2005)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
por: Masuishi, Toshiki, et al.
Publicado: (2023)

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2016)

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
por: Liu, Yuguo, et al.
Publicado: (2015)

FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
por: Zhang, Xiaowei, et al.
Publicado: (2022)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
por: Teufel, Andreas, et al.
Publicado: (2004)

Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study
por: Jarząbek, Magdalena, et al.
Publicado: (2011)

Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients
por: Helmberger, Thomas, et al.
Publicado: (2022)

Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only
por: Li, Ching-Chun, et al.
Publicado: (2022)

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis
por: Chen, Ke, et al.
Publicado: (2016)

Transarterial Chemoembolization with Irinotecan-loaded Beads Followed by Arterial Infusion of 5-Fluorouracil for Metastatic Liver Tumors Refractory to Standard Systemic Chemotherapy
por: Irizato, Mariko, et al.
Publicado: (2023)

Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy
por: Bishay, VL, et al.
Publicado: (2014)

Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies
por: Schicho, Andreas, et al.
Publicado: (2018)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases
por: Vogl, Thomas J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3k795muudm686of1nval2sevkk